This is a StreetInsider.com Premium Only Page

(ATNX) – StreetInsider.com Reports

Apr 26, 2023 05:49 AM Athenex (ATNX) Appoints Nick Campbell as Chief Restructuring Officer

Mar 21, 2023 06:42 AM Ladenburg Thalmann Downgrades Athenex (ATNX) to Neutral

Feb 14, 2023 08:00 AM Athenex (ATNX) Announces 1:20 Reverse Stock Split

Jan 3, 2023 08:01 AM Athenex (ATNX) Announces Negative MHRA Decision on Oral Paclitaxel

Dec 20, 2022 08:16 AM Athenex (ATNX) Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial

Dec 16, 2022 08:02 AM Athenex (ATNX) Exits 503B Sterile Compounding Business

Nov 22, 2022 10:30 AM Athenex (ATNX) Announces Positive Results of Special Stockholder Meeting

Nov 3, 2022 07:05 AM Athenex (ATNX) Receives Positive Nasdaq Listing Determination

Aug 11, 2022 05:39 AM Athenex (ATNX) Prices 35.33M Share Offering at $0.75/sh

Aug 10, 2022 04:01 PM Athenex (ATNX) Announces Proposed Stock Offering, Size not Disclosed

Aug 5, 2022 09:17 AM Pre-Open Movers: iRobot Surges on Amazon Takeover, Twilio Lower on Results

Aug 5, 2022 02:41 AM Athenex (ATNX) option IV low at 20

Aug 4, 2022 05:56 PM After-Hours Movers: Cloudflare, DoorDash Gain on EPS; Warner Bros. Discovery Sinks

Aug 4, 2022 05:50 PM Athenex (ATNX) Surges on Takeover Chatter

Jul 28, 2022 07:12 AM Athenex, Inc. (ATNX) Misses Q2 EPS by 13c

Jul 25, 2022 10:00 AM Athenex (ATNX) Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clin

Jul 25, 2022 10:00 AM Athenex (ATNX) Reports Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel

Jul 15, 2022 12:26 PM Athenex (ATNX) received a Notice of Allowance for its US patent application - Patent Grants

Jul 11, 2022 08:00 AM Athenex (ATNX) Sells China API Business to TiHe Capital for $19M

Jun 22, 2022 08:34 AM Athenex (ATNX) Sells Revenues from U.S. and European Royalty and Milestone Interests in Klisyri to Sagard Healthcare Partners and Oaktree for $80M

Jun 8, 2022 08:05 AM Athenex (ATNX) Appoints Darrel P. Cohen as Chief Medical Officer of Cell Therapy

May 10, 2022 03:41 PM Athenex (ATNX) PT Lowered to $5 at Laidlaw

Apr 25, 2022 08:09 AM Athenex (ATNX) Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 in Relapsed or Refractory Lymphoma and Leukemia

Mar 17, 2022 06:10 AM Athenex (ATNX) PT Lowered to $4 at RBC Capital

Feb 22, 2022 08:05 AM Athenex (ATNX) Appoints Joe Annoni as CFO

Jan 12, 2022 08:33 AM Athenex (ATNX) Announces Agreement with ImmunityBio (IBRX) Regarding Dunkirk Manufacturing Facility

Jan 12, 2022 08:32 AM ImmunityBio (IBRX) Expands Manufacturing Capacity with State-of-the-Art Manufacturing Plant in New York for Global Pandemic Response and Preparedness

Nov 29, 2021 08:29 AM Athenex (ATNX) Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Nov 9, 2021 08:02 AM Athenex (ATNX) Enters Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR

Nov 4, 2021 09:17 AM Athenex (ATNX) Reports Interim Data from ANCHOR Study of KUR-502

Oct 11, 2021 01:29 PM Athenex (ATNX) PT Lowered to $9 at Laidlaw

Oct 11, 2021 01:24 PM Athenex (ATNX) PT Lowered to $5 at RBC Capital

Oct 11, 2021 08:00 AM Athenex (ATNX) Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer

Sep 27, 2021 08:04 AM Athenex (ATNX) Announces Phased European Launch of Klisyri for Treatment of Actinic Keratosis

Aug 6, 2021 06:16 AM Athenex (ATNX) PT Lowered to $8 at RBC Capital

Jul 27, 2021 06:14 AM Athenex (ATNX) Files $300M Mixed Shelf

Jul 26, 2021 07:04 AM Athenex (ATNX) Announces Additional Licensing Agreements for Tirbanibulin

Jul 19, 2021 10:52 AM Athenex (ATNX) Announces European Commission Approval of Klisyri for the Topical Treatment of Actinic Keratosis

Jul 7, 2021 06:48 AM Athenex (ATNX) PT Lowered to $7.50 at Ladenburg Thalmann

Jul 6, 2021 07:02 AM Athenex (ATNX) Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

May 21, 2021 09:22 AM Athenex (ATNX) Announces Klisyri Receives Positive CHMP Opinion from EMA for Treatment of Actinic Keratosis of Face or Scalp

May 11, 2021 08:50 AM Athenex (ATNX) PT Lowered to $4.50 at JPMorgan

May 5, 2021 09:51 AM Increasing unusual option volume: ATNX IBIO BGFV

May 5, 2021 09:30 AM Pre-Open Movers 05/05: (CHMA) (ATNX) (IBIO) Higher; (COCP) (ESPR) (MCFE) Lower (more...)

May 4, 2021 05:32 PM Athenex (ATNX) to Acquire Kuur Therapeutics to Expand Cell Therapy Development with Off-the-Shelf Engineered CAR-NKT Platform

Mar 2, 2021 06:48 AM Athenex (ATNX) PT Lowered to $12 at Ladenburg Thalmann

Mar 2, 2021 05:39 AM Athenex (ATNX) PT Lowered to $9 at RBC Capital

Mar 2, 2021 12:29 AM Truist Securities Downgrades Athenex (ATNX) to Hold

Mar 1, 2021 04:29 PM UPDATE: JPMorgan Downgrades Athenex (ATNX) to Neutral

Mar 1, 2021 04:26 PM SVB Leerink Downgrades Athenex (ATNX) to Market Perform